Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy?

J Natl Cancer Inst. 2023 Jun 8;115(6):605-607. doi: 10.1093/jnci/djac016.

Authors

Michael T Milano¹, Joseph K Salama², Steven J Chmura³

Affiliations

¹ Department of Radiation Oncology, University of Rochester, Rochester, NY, USA.
² Department of Radiation Oncology, Duke University School of Medicine, Durham, NC, USA.
³ Departments of Radiation and Cellular Oncology and Medicine, Pritzker School of Medicine, University of Chicago, Chicago, IL, USA.

No abstract available

Publication types

Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Carcinoma, Non-Small-Cell Lung* / radiotherapy
ErbB Receptors / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Lung Neoplasms* / radiotherapy
Radiation Oncology*
Treatment Outcome

Substances

ErbB Receptors
EGFR protein, human